BIOCRYST PHARMACEUTICALS INC (BCRX)
US09058V1035 - Common Stock
Taking everything into account, BCRX scores 2 out of 10 in our fundamental rating. BCRX was compared to 588 industry peers in the Biotechnology industry. BCRX has a bad profitability rating. Also its financial health evaluation is rather negative. BCRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BCRX has reported negative net income.
In the past year BCRX has reported a negative cash flow from operations.
BCRX had negative earnings in each of the past 5 years.
BCRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
BCRX has a Return On Assets (-43.82%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.82% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-40.02%
ROA(5y)-47.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 98.59%, BCRX belongs to the best of the industry, outperforming 98.80% of the companies in the same industry.
BCRX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BCRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
BCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BCRX has been increased compared to 1 year ago.
BCRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BCRX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -3.24, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
BCRX has a Altman-Z score (-3.24) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.24 |
ROIC/WACCN/A
WACC5.91%
2.3 Liquidity
BCRX has a Current Ratio of 3.31. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
BCRX has a Current ratio of 3.31. This is in the lower half of the industry: BCRX underperforms 63.18% of its industry peers.
A Quick Ratio of 3.12 indicates that BCRX has no problem at all paying its short term obligations.
BCRX's Quick ratio of 3.12 is on the low side compared to the rest of the industry. BCRX is outperformed by 63.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.12 |
3. Growth
3.1 Past
BCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.56%, which is quite impressive.
BCRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.37%.
The Revenue has been growing by 74.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)25.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q26.32%
Revenue 1Y (TTM)22.37%
Revenue growth 3Y165.04%
Revenue growth 5Y74.13%
Revenue growth Q2Q17.41%
3.2 Future
The Earnings Per Share is expected to grow by 26.49% on average over the next years. This is a very strong growth
Based on estimates for the next years, BCRX will show a quite strong growth in Revenue. The Revenue will grow by 19.21% on average per year.
EPS Next Y37%
EPS Next 2Y28.34%
EPS Next 3Y26.5%
EPS Next 5Y26.49%
Revenue Next Year20.71%
Revenue Next 2Y20.47%
Revenue Next 3Y19.77%
Revenue Next 5Y19.21%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BCRX's earnings are expected to grow with 26.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.34%
EPS Next 3Y26.5%
5. Dividend
5.1 Amount
No dividends for BCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOCRYST PHARMACEUTICALS INC
NASDAQ:BCRX (4/24/2024, 7:00:01 PM)
After market: 4.23 +0.02 (+0.48%)4.21
-0.17 (-3.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap867.89M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.82% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.59% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.12 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)25.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.37%
Revenue growth 3Y165.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y